SCHEMBL1491207

SCHEMBL1491207

Nc1cccnc1S(=O)(=O)O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.54
KDM4E B2RXH2 3/20 0.43
ALOX12 P18054 1/20 0.43
TTR P02766 1/20 0.41
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA9 Q16790 1/20 0.40
COMT P21964 1/20 0.40
NAPRT Q6XQN6 2/20 0.39
HSP90AA1 P07900 2/20 0.39
HSP90AB1 P08238 2/20 0.39
ALDH1A1 P00352 3/20 0.38
TDP1 Q9NUW8 2/20 0.38
LMNA P02545 1/20 0.38
MAPT P10636 1/20 0.38
HTT P42858 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
CYP1A2 P05177 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10936188 0.83 KMT2A (0.68) KMT2ACA12CA1CA2CA9
SCHEMBL390770 0.81 KMT2A (0.56) KMT2AKDM4EALOX12CA12CA1
SCHEMBL8517377 0.79 KMT2A (0.54) KMT2AKDM4ECA12CA1CA2
SCHEMBL30908297 0.79 KMT2A (0.59) KMT2ACA12CA1CA2CA9
SCHEMBL18230355 0.79 KMT2A (0.59) KMT2ACA12CA1CA2CA9
SCHEMBL7081072 0.77 KDM4E (0.53) KMT2AKDM4EALOX12COMTNAPRT
SCHEMBL2112972 0.77 COMT (0.49) KMT2AKDM4EALOX12TTRCA1
SCHEMBL29564068 0.77 COMT (0.49) KMT2AKDM4EALOX12TTRCA1
SCHEMBL28502273 0.77 NFE2L2 (0.43) KDM4EALOX12COMTNAPRTLMNA
SCHEMBL21061787 0.76 KMT2A (0.56) KMT2AKDM4ECA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-1997007100-A1 PROCESS FOR THE PRODUCTION OF HYDROXYPYRIDINE SULFONIC ACIDS NOVARTIS AG (CH) 1997-02-27 WO claimed
CN-105088311-B A kind of aluminium alloy is without nickel environmental protection hole sealing agent 深圳前海艾丽优科技有限公司 2018-07-24 CN disclosed
EP-2968342-A1 COMPOSITIONS COMPRISING THIENOPYRIMIDINE AND THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF The Regents Of The University Of Michigan (US) 2016-01-20 EP disclosed
CN-105088311-A Aluminum alloy nickel-free environment-friendly hole sealing agent SHENZHEN QIANHAI AILIYOU TECHNOLOGY CO LTD 2015-11-25 CN disclosed
WO-2014164543-A1 COMPOSITIONS COMPRISING THIENOPYRIMIDINE AND THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2014-10-09 WO disclosed
US-7897635-B2 HIV protease inhibitors THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2011-03-01 US disclosed
CN-101048403-B Heterocyclic antiviral compounds HOFFMANN LA ROCHE 2010-06-16 CN disclosed
US-20080075686-A1 Deodorizer and method for using the same TOTO LTD. (JP) 2008-03-27 US disclosed
CN-101048403-A Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (CH) 2007-10-03 CN disclosed
US-20070082883-A1 HIV protease inhibitors THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2007-04-12 US disclosed
US-7157489-B2 HIV protease inhibitors THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2007-01-02 US disclosed
EP-1485387-A1 CARBAMATES AS HIV PROTEASE INHIBITORS BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2004-12-15 EP disclosed
US-20040039016-A1 HIV protease inhibitors NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2004-02-26 US disclosed
WO-2003078438-A1 CARBAMATES AS HIV PROTEASE INHIBITORS THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2003-09-25 WO disclosed
WO-1997007100-A1 PROCESS FOR THE PRODUCTION OF HYDROXYPYRIDINE SULFONIC ACIDS NOVARTIS AG (CH) 1997-02-27 WO disclosed
WO-1997007100-A1 PROCESS FOR THE PRODUCTION OF HYDROXYPYRIDINE SULFONIC ACIDS NOVARTIS AG (CH) 1997-02-27 WO disclosed
CN-1094028-A Selective PDE enzyme (IV) inhibitor catechol diether class PFIZER (US) 1994-10-26 CN disclosed
CN-86100895-A GOLD ELECTROPLATING BATH 1986-07-16 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070082883-A1 HIV protease inhibitors SERPINB1, TMPRSS15, DNPEP KMT2A 3671/4885KDM4E 2514/4885ALOX12 3788/4885
US-20040039016-A1 HIV protease inhibitors SERPINB1, TMPRSS15, DNPEP KMT2A 3671/4885KDM4E 2514/4885ALOX12 3788/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.